Stay updated with breaking news from Abionyx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:
Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the
Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:
2022 revenues: €5.3 million Reduction of the annual operating loss Cash position of €4 million as of December 31, 2022 Continued clinical development following the succession
Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: